Has AbbVie Inc. had other FDA enforcement actions?

Yes. Argus HQ has recorded 4 total FDA actions tied to AbbVie Inc.: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.

What kind of FDA record is this?

This is an Argus HQ record of a FDA Recall, tagged medium severity by Argus HQ. FDA published the underlying record on 2023-11-15; Argus observed and indexed it on 2026-07-16.

Where can I verify this record directly with FDA?

The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

.hq

fda_recall · drug_recall · medium

AbbVie Inc. — Class III recall: Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle,…

Name: FDA Recall Record — AbbVie Inc.
Creator: Argus HQ
Published: 2023-11-15
License: https://argushq.ai/methodology

Event date: 2023-11-15 00:00:00Z
Observed: 2026-07-16 23:20:07Z
Source ID: D-0088-2024
Payload hash: 08f23fe3cb46d5c52c0b38d7…

Summary

Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose. Status: Ongoing.

Entities

AbbVie Inc.

View source record ↗

Frequently asked questions

Has AbbVie Inc. had other FDA enforcement actions?: Yes. Argus HQ has recorded 4 total FDA actions tied to AbbVie Inc.: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.
What kind of FDA record is this?: This is an Argus HQ record of a FDA Recall, tagged medium severity by Argus HQ. FDA published the underlying record on 2023-11-15; Argus observed and indexed it on 2026-07-16.
Where can I verify this record directly with FDA?: The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2023). AbbVie Inc. — Class III recall: Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle,…. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/events/fda-recall-abbvie-inc-d-0088-2024

MLA

"AbbVie Inc. — Class III recall: Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle,…." Argus HQ Research, Digital Empire Holdings LLC, 2023, argushq.ai/events/fda-recall-abbvie-inc-d-0088-2024.

Chicago

Argus HQ Research. "AbbVie Inc. — Class III recall: Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle,…." Digital Empire Holdings LLC. Accessed July 23, 2026. https://argushq.ai/events/fda-recall-abbvie-inc-d-0088-2024.

BibTeX

@misc{argushq_argushq_ai_events_fda_recall_abbvie_inc_d_0088_2024_2023,
  title = {AbbVie Inc. — Class III recall: Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle,…},
  author = {{Argus HQ Research}},
  year = {2023},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/events/fda-recall-abbvie-inc-d-0088-2024},
  note = {Accessed: July 23, 2026}
}

Informational only. Not legal, financial, or medical advice.